Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending June 30, 2026, and highlighted continued progress across the RAP-219 development program and pipeline. "We remain focused on disciplined execution as we deliver against several important catalysts this year," said Abraham N.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
RAPP	William Blair	Outperform	undefined >> undefined	July 28th 2026

Press releases

05.08.2026

Rapport Therapeutics, Inc. (RAPP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Videos

No Data

Upgrades / Downgrades

Press releases

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Search stocks

Rapport Therapeutics, Inc. (RAPP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Videos

No Data

Upgrades / Downgrades

Press releases

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update